A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Clinical trial NCT07667322 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07667322
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-17
- Primary completion
- 2028-02-15
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.